A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...